26 results
10-K
2022 FY
EX-14.1
SCNI
Scinai Immunotherapeutics Ltd
17 Apr 23
Annual report
4:06pm
and with Company policies and procedures? (ii) Would you or the Company be compromised or embarrassed if the situation were known by your co-workers or the public
10-K
2022 FY
SCNI
Scinai Immunotherapeutics Ltd
17 Apr 23
Annual report
4:06pm
-borne pathogens and the handling of biohazardous materials and chemicals. Although we maintain workers’ compensation insurance to cover the costs
424B5
SCNI
Scinai Immunotherapeutics Ltd
28 Dec 21
Prospectus supplement for primary offering
5:20pm
laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials and chemicals. Although we maintain workers’ compensation
424B5
SCNI
Scinai Immunotherapeutics Ltd
27 Dec 21
Prospectus supplement for primary offering
6:22am
and the handling of biohazardous materials and chemicals. Although we maintain workers’ compensation insurance to cover the costs and expenses that may be incurred
424B5
wuzq72e
1 Feb 21
Prospectus supplement for primary offering
5:08pm
424B5
mcq51fs1eq0 pt
29 Jan 21
Prospectus supplement for primary offering
12:00am
6-K
EX-99.3
7da4et jc1cfcz
2 Oct 20
Condensed Interim Financial Statements
12:00am
424B5
461pem67 kq6
2 Oct 20
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
9htw9vdi1886o 4wa
1 Sep 20
Report of Foreign Private Issuer
7:18am
POS AM
odloiq
7 Jan 20
Prospectus update (post-effective amendment)
10:51am
F-1/A
d1jo covcuca
7 Jun 19
Registration statement (foreign) (amended)
11:42am
F-1/A
b5o94rushap
6 Jun 19
Registration statement (foreign) (amended)
12:00am
F-1/A
4g6ziwka
30 May 19
Registration statement (foreign) (amended)
8:46am
F-1/A
cg21wd rcjeh4m2y
6 May 19
Registration statement (foreign) (amended)
10:03am